In vitro activity of daptomycin against gram-positive European clinical isolates with defined resistance determinants.
about
Daptomycin in paediatrics: current knowledge and the need for future researchIn vitro activities of ceftobiprole, tigecycline, daptomycin, and 19 other antimicrobials against methicillin-resistant Staphylococcus aureus strains from a national survey of Belgian hospitalsIn vitro activity of daptomycin against methicillin-resistant Staphylococcus aureus, including heterogeneously glycopeptide-resistant strains.Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci and vancomycin-resistant enterococci isolated in European medical centers (2005).Diabetic foot infections: microbiological aspects, current and future antibiotic therapy focusing on methicillin-resistant Staphylococcus aureus.Multicenter evaluation of the Etest and disk diffusion methods for differentiating daptomycin-susceptible from non-daptomycin-susceptible Staphylococcus aureus isolates.Potential chitosan-coated alginate nanoparticles for ocular delivery of daptomycin.In vitro activity of para-guanidinoethylcalix[4]arene against susceptible and antibiotic-resistant Gram-negative and Gram-positive bacteria.Safety and efficacy of daptomycin in the treatment of osteomyelitis: results from the CORE Registry.Effect of daptomycin on local interleukin-6, matrix metalloproteinase-9, and metallopeptidase inhibitor 1 in patients with MRSA-infected diabetic foot.Daptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections.Effect of daptomycin on local interleukin-6, matrix metalloproteinase-9, and metallopeptidase inhibitor 1 in patients with MRSA-infected diabetic foot.Daptomycin-rifampin for a recurrent MRSA joint infection unresponsive to vancomycin-based therapy.
P2860
Q27006038-E0731A87-E075-4CDA-B1E7-27AA1E1C06E2Q34973784-5687D2ED-3A97-4CD9-8D99-EC60D1335554Q35023234-FE65891E-7521-47D2-B986-418DAA10A0E9Q35782816-9A8686E5-8125-42F3-AF3A-9DE8B1923B53Q37924980-448FBCCA-1434-49A3-9098-2A97592E679CQ38474869-640646CF-7081-497F-B846-13D1B4BD5597Q38901841-17B19C1D-4121-4653-8DE7-29615B345020Q40108198-700645F3-8DB6-4D96-892C-062C96018C88Q43997965-451183BE-2017-471E-BE91-2C12441A97A7Q44561865-5A99E4F8-B838-452C-A879-6F19F53FD647Q45230598-6AED481C-2E48-4866-8E67-52C2EF2E8142Q45752409-FE1CF315-8EB8-4D7E-BEB7-A287E02C6C17Q46921060-579FE2BD-3670-4F87-8EE6-E93D66D055EC
P2860
In vitro activity of daptomycin against gram-positive European clinical isolates with defined resistance determinants.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
In vitro activity of daptomyci ...... fined resistance determinants.
@ast
In vitro activity of daptomyci ...... fined resistance determinants.
@en
type
label
In vitro activity of daptomyci ...... fined resistance determinants.
@ast
In vitro activity of daptomyci ...... fined resistance determinants.
@en
prefLabel
In vitro activity of daptomyci ...... fined resistance determinants.
@ast
In vitro activity of daptomyci ...... fined resistance determinants.
@en
P2093
P2860
P1476
In vitro activity of daptomyci ...... fined resistance determinants.
@en
P2093
Ad C Fluit
Dana Milatovic
Franz-Josef Schmitz
Jan Verhoef
P2860
P304
P356
10.1128/AAC.48.3.1007-1011.2004
P407
P577
2004-03-01T00:00:00Z